Marktanalyse - Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market

Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market

Summary

GBI Research, a leading business intelligence provider, has released its latest research 'Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market”. The report provides in-depth analysis of the drivers and barriers that affect the global Women’s Health market and analyzes the markets for women’s health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenues and annual cost of therapy are forecast until 2017 for the key geographies, as well as for the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the women’s health therapeutics market will grow rapidly, largely due to the introduction of new therapies and the increased awareness among patients and physicians in two of the largest segments within WH disorders, the menopause and osteoporosis. Novel non-hormonal therapeutics will become more popular during the forecast period. Though many of the major selling drugs in the osteoporosis market are set to lose patent protection in 2012, the launch of effective therapies such as Prolia (recently launched in 2010) will drive the market revenues. The overall women’s health therapeutics market is driven by postmenopausal osteoporosis and menopause. The endometriosis market is heavily genericized and lacks an effective and safe option for the treatment of endometriosis.
In 2010, the women’s health therapeutics market was estimated to be worth $14,530m. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 7.9% between 2010 and 2017 to record a sales value of $24,671m in 2017.

The market has considerable unmet need, as the majority of the diseases in the market are served by hormonal therapeutics. Hormones have been shown to be associated with significant safety issues such as risks of breast cancer and cardiovascular disease. Hence, the use of hormones has declined and women are worried about resuming hormonal therapy for the treatment of the menopause/osteoporosis. There is an opportunity for pharmaceutical companies to develop drugs with greater safety profiles and more competitive prices.

The women’s health therapeutics market R&D pipeline is moderately strong, with the majority of first-in-class drugs in late stages of development. These drugs are expected to drive market revenues and it is expected that, if they are approved and are shown to have better safety profiles, patients will comply with novel therapies. In particular, non-hormones are set to take over the conventional hormone therapeutics market.

Scope

- Annualized market data for the women’s health disorders market from 2002 to 2010, forecast to 2017.
- Analysis of the leading therapeutic segments, including endometriosis, postmenopausal osteoporosis, menopause and urinary incontinence
- Analysis of the women’s health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan
- Market characterization of the women’s health therapeutics market, including market size, annual cost of therapy and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck and Warner Chilcott Plc.
- Key M&A activities and licensing agreements that took place in 2010 in the women’s health therapeutics market

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.


Press Release:

GBI Research, a leading business intelligence provider, has released its latest research 'Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Markets”. The report provides in-depth analysis of the drivers and barriers that affect the Women’s Health market and analyzes the markets for women’s health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenues, annual cost of therapy and treatment flow algorithm are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. The report also includes insights into the respiratory disorders R&D product pipeline.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Global Women’s Health Therapeutics Market is Forecast to Grow Rapidly from 2010 to 2017
In 2010, the global women’s health therapeutics market was estimated to be worth $14,530m, after a Compound Annual Growth Rate (CAGR) of 3.5% between 2002 and 2010. By 2017 the market is estimated to reach $24,671m, indicating a CAGR of 7.9% between 2010 and 2017. Owing to several factors such as the publication of the Women’s Health Initiative (WHI) study results, and a lack of effective therapeutics, the women’s health therapeutics market grew only moderately between 2002 and 2010. However, the launch of novel therapeutics in the near future is expected to satisfy the unmet need in the market. This will have a pronounced effect on positive growth in the menopause therapeutics market.

Women’s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017

Source: GBI Research, North American Menopause Society, Japan Menopause Society, WHI, , National Osteoporosis Society, American Journal of Epidemiology, FDA, Pubmed, European Endometriosis Alliance, Japan Endometriosis Association, Company Websites

The current women’s health therapeutics pipeline is promising, with a strong line-up of first-in-class molecules in late stages of clinical development such as Pristiq (desvenlafaxine), Aprela (bazedoxifene/conjugated estrogens), Menerba (MF101) and Elagolix (NBI-56418). In addition, the recent launch of potential blockbuster drugs such as Prolia (denosumab) for the treatment of postmenopausal osteoporosis will offset the patent expirations of several major drugs, including Fosamax (alendronate sodium), Boniva (ibandronate sodium) and Actonel (risedronate sodium). The women’s health therapeutics market is an attractive market with huge opportunities for novel entrants with high safety and efficacy profiles.

Novel Therapies are Poised to Dominate the Women’s Health Disorder Therapeutics Market

The women’s health therapeutics market is backed by a strong pipeline which is expected to drive the growth of this market. Major players such as Pfizer, Inc. and Merck & Co., Inc. have attractive pipelines with many first-in-class molecules for the treatment of the menopause, osteoporosis and endometriosis. If approved, a trend shift in the treatment pattern will be seen, particularly in the menopause and osteoporosis markets.

Amgen Inc recently launched Prolia, a first-in-class drug for the treatment of postmenopausal osteoporosis. Merck’s Odanacatib (MK-0822), a cathepsin K inhibitor, has also shown promising results in postmenopausal osteoporosis treatment. The menopause therapeutics market is presently dominated by hormone therapeutics with highly questionable safety profiles. If approved for treatment and shown to be safer, non-hormones for the treatment of menopause will strongly compete with the currently marketed drugs and will significantly alter the market dynamics, with the potential to drive the menopause market sales up to $7,567m by 2017.

Deals Worth Less than $ 1,000m Accounted for 85% of Strategic Consolidations

Women’s Health Therapeutics Market, Global, M&A Deals by Value, (%), 2004-2011

Source: GBI Research, Company Websites

Strategic consolidations help a company to enter a new market or consolidate its position in the market. The majority (85%) of the merger and acquisition (M&A) deals in the women’s health therapeutics market were worth less than $1,000m. Abbott will gain full control of two drugs Tricor (fenofibrate) and Trilipix (fenofibric acid), for treating cholesterol and triglycerides.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 8

2 Women’s Health Therapeutics Market to 2017 - Introduction 10

2.1 GBI Research Report Guidance 11

3 Women’s Health Therapeutics Market to 2017 - Market Overview 12

3.1 Introduction 12

3.2 Revenue Forecasts for Women’s Health Therapeutics Market 12

3.2.1 Revenues 12

3.2.2 Annual Cost of Therapy 16

3.2.3 Generic Share 17

3.3 Treatment Usage Patterns 18

3.4 Drivers and Barriers for Women’s Health Therapeutics Market 20

3.4.1 Drivers for Women’s Health Therapeutics Market 20

3.4.2 Barriers for Women’s Health Therapeutics Market 20

4 Women’s Health Therapeutics Market to 2017 - Geographical Landscape 21

4.1 The US 21

4.1.1 Revenue 21

4.1.2 Annual Cost of Therapy 22

4.1.3 Treatment Usage Pattern 23

4.2 Top Five Countries of Europe 25

4.2.1 Revenue 25

4.2.2 Annual Cost of Therapy 26

4.2.3 Treatment Usage Pattern 27

4.3 Japan 29

4.3.1 Revenue 29

4.3.2 Annual Cost of Therapy 30

4.3.3 Treatment Usage Pattern 31

5 Women’s Health Therapeutics Market to 2017 - Therapeutic Landscape 33

5.1 Menopause 33

5.1.1 Introduction 33

5.1.2 Revenues 34

5.1.3 Generic Share 38

5.1.4 Annual Cost of Therapy 39

5.1.5 Treatment Usage Patterns 40

5.1.6 Drivers and Barriers for Menopause 42

5.2 Post Menopausal Osteoporosis 43

5.2.1 Introduction 43

5.2.2 Revenues 44

5.2.3 Generic Share 47

5.2.4 Annual Cost of Therapy 48

5.2.5 Treatment Usage Patterns 49

5.2.6 Treatment Flow Algorithm 51

5.2.7 Drivers and Barriers for Post Menopausal Osteoporosis 52

5.3 Endometriosis 53

5.3.1 Introduction 53

5.3.2 Revenues 54

5.3.3 Generic Share 57

5.3.4 Annual Cost of Therapy 58

5.3.5 Treatment Usage Patterns 59

5.3.6 Treatment Flow Algorithm 61

5.3.7 Drivers and Barriers for Endometriosis 62

5.4 Urinary Incontinence 63

5.4.1 Introduction 63

5.4.2 Revenues 65

5.4.3 Generic Share 68

5.4.4 Annual Cost of Therapy 69

5.4.5 Treatment Usage Patterns 71

5.4.6 Treatment Flow Algorithm 73

5.4.7 Drivers and Barriers for Urinary Incontinence 74

6 Women’s Health Therapeutics Market to 2017 - Pipeline Analysis 75

6.1 Introduction 75

6.1.1 Research and Development Pipeline - Menopause 77

6.1.2 Research and Development Pipeline - Postmenopausal Osteoporosis 78

6.1.3 Research and Development Pipeline - Endometriosis 80

6.1.4 Research and Development Pipeline - Urinary Incontinence 81

6.2 Profiles of Promising Drugs in the Women’s Health Therapeutics Market 82

6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen) 82

6.2.2 Pristiq (Desvenlaxafine, DVS-233) 83

6.2.3 Visanne 84

6.2.4 Elagolix (NBI-56418) 85

6.2.5 Odanacatib (MK-0822) 85

6.2.6 Viviant (Bazedoxifene) 86

6.2.7 YM178 87

6.2.8 GRC 6211 88

7 Women’s Health Therapeutics Market to 2017- Competitive Landscape 89

7.1 Market Share Analysis - Women’s Health Therapeutics Market 89

7.2 Major Marketed Products: Women’s Health Therapeutics Market 90

7.2.1 Detrol (tolterodine tartrate) 90

7.2.2 Premarin 90

7.2.3 Evista (raloxifene hydrochloride) 90

7.2.4 Actonel (Risedronate sodium) 90

7.3 Competitive Profiling 91

7.3.1 Pfizer 91

7.3.2 Eli-Lilly 92

7.3.3 Merck 93

7.3.4 Roche 94

7.3.5 Warner Chilcott 95

8 Women’s Health Therapeutics Market to 2017 - M&A Landscape 96

8.1 M&A Landscape 96

8.1.1 M&A Deals by Year 96

8.1.2 M&A Deals by Deal Type 97

8.1.3 M&A Deals by Geography 98

8.1.4 M&A Deals by Value 99

8.1.5 Top Five M&A Deals by Value 100

8.2 R&D Licensing Agreements 101

8.2.1 Deals by Year 101

8.2.2 Deals by Geography 102

8.2.3 Deals by Value ($) 103

8.3 Co-Development Agreements 104

8.3.1 Co-Development Agreements by Year 104

8.3.2 Co-Development Agreements by Geography 105

8.3.3 Co-Development Agreements by Value 106

9 Women’s Health Therapeutics Market to 2017 - Appendix 107

9.1 Market Definitions 107

9.2 Abbreviations 107

9.3 Research Methodology 108

9.3.1 Coverage 108

9.3.2 Secondary Research 108

9.3.3 Primary Research 109

9.3.4 Section Wise Methodology 109

9.3.5 Expert Panel Validation 113

9.4 Contact Us 113

9.5 Disclaimer 113

9.6 Sources 113



1.1 List of Tables

Table 1: Women’s Health Therapeutics Market, Global, Revenue, ($m), 2002 - 2010 12

Table 2: Women’s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017 13

Table 3: Women’s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010 14

Table 4: Women’s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017 15

Table 5: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010 16

Table 6: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017 16

Table 7: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010 18

Table 8: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017 19

Table 9: Women’s Health Therapeutics Market, The US, Revenue, ($m), 2002 - 2010 21

Table 10: Women’s Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2010 - 2017 21

Table 11: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2010 22

Table 12: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2010 - 2017 22

Table 13: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2010 23

Table 14: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2010 - 2017 24

Table 15: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue, ($m), 2002 - 2010 25

Table 16: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2010 - 2017 25

Table 17: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2010 26

Table 18: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2010 - 2017 26

Table 19: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2010 27

Table 20: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2010 - 2017 28

Table 21: Women’s Health Therapeutics Market, Japan, Revenue, ($m), 2002 - 2010 29

Table 22: Women’s Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2010 - 2017 29

Table 23: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2010 30

Table 24: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010- 2017 30

Table 25: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2010 31

Table 26: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2010 - 2017 32

Table 27: Menopause Therapeutics Market, Global, Revenue, ($m), 2002 - 2010 34

Table 28: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017 34

Table 29: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010 36

Table 30: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2010 -2017 37

Table 31: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010 39

Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017 39

Table 33: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010 40

Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017 41

Table 35: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010 44

Table 36: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017 44

Table 37: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010 45

Table 38: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017 46

Table 39: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010 48

Table 40: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017 48

Table 41: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010 49

Table 42: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017 50

Table 43: Endometriosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010 54

Table 44: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017 54

Table 45: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010 55

Table 46: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017 56

Table 47: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 58

Table 48: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 58

Table 49: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002 - 2010 59

Table 50: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010 - 2017 60

Table 51: Urinary Incontinence Therapeutics Market, Global, Revenue, ($m), 2002 - 2010 65

Table 52: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017 65

Table 53: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010 66

Table 54: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017 67

Table 55: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010 69

Table 56: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017 69

Table 57: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010 71

Table 58: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017 72

Table 59: Women’s Health Therapeutics Market, Global, Pipeline by Phase, 2011 75

Table 60: Women’s Health Therapeutics Market, Global, Pipeline by Indication, 2011 76

Table 61: Menopause Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011 77

Table 62: Menopause Therapeutics Market, Global, Pipeline, IND Filed Stage Molecules, 2011 77

Table 63: Menopause Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011 77

Table 64: Menopause Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011 77

Table 65: Menopause Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011 77

Table 66: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011 78

Table 67: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011 78

Table 68: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011 79

Table 69: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011 79

Table 70: Endometriosis Therapeutics Market, Pipeline, Global, Pre-Clinical Stage Molecules, 2011 80

Table 71: Endometriosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011 80

Table 72: Endometriosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011 80

Table 73: Endometriosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011 80

Table 74: Urinary Incontinence Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011 81

Table 75: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011 81

Table 76: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011 81

Table 77: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011 82

Table 78: Urinary Incontinence Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011 82

Table 79: Women’s Health Therapeutics Market, Marketed Drug Revenues, 2010 90

Table 80: Women’s Health Therapeutics Market, Global, M&A Deals by Type, 2004-2011 97

Table 81: Women’s Health Therapeutics Market, Global, M&A Deals by Geography, 2004-2011 98

Table 82: Women’s Health Therapeutics Market, Global, M&A Deals by Value, 2004-2011 99

Table 83: Women’s Health Therapeutics Market, Global, Top Five M&A Deals by Value, ($m), 2005-2010 100

Table 84: Women’s Health Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011 102

Table 85: Women’s Health Therapeutics Market, Global, Licensing Agreements by Value, ($m), 2004-2011 103

Table 86: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Geography, 2004-2011 105

Table 87: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Value, ($m), 2004-2011 106



1.2 List of Figures

Figure 1: Women’s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017 12

Figure 2: Women’s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017 14

Figure 3: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017 16

Figure 4: Women’s Health Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017 17

Figure 5: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017 18

Figure 6: Women’s Health Therapeutics Market, Global, Drivers and Barriers, 2010 20

Figure 7: Women’s Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2002 - 2017 21

Figure 8: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2017 22

Figure 9: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2017 23

Figure 10: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2002 - 2017 25

Figure 11: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002 - 2017 26

Figure 12: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2017 27

Figure 13: Women’s Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2002 - 2017 29

Figure 14: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2017 30

Figure 15: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2017 31

Figure 16: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017 34

Figure 17: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017 36

Figure 18: Menopause Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017 38

Figure 19: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017 39

Figure 20: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017 40

Figure 21: Menopause Therapeutics Market, Global, Drivers and Barriers, 2010 42

Figure 22: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017 44

Figure 23: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017 45

Figure 24: Post Menopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017 47

Figure 25: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017 48

Figure 26: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017 49

Figure 27: Post Menopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm, 2010 51

Figure 28: Post Menopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers, 2010 52

Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017 54

Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017 55

Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017 57

Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 58

Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002 - 2017 59

Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm, 2010 61

Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers, 2010 62

Figure 36: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017 65

Figure 37: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017 66

Figure 38: Urinary Incontinence Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017 68

Figure 39: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017 69

Figure 40: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017 71

Figure 41: Women’s health Therapeutics to 2017, UI Treatment Algorithm Part-1 73

Figure 42: Women’s Health Therapeutics to 2017, UI Treatment Algorithm, Part-2 73

Figure 43: Urinary Incontinence Therapeutics Market, Global, Drivers and Barriers, 2010 74

Figure 44: Women’s Health Therapeutics Market, Global, Pipeline by Phase, (%), 2011 75

Figure 45: Women’s Health Therapeutics Market, Global, Pipeline by Indication (%), 2011 76

Figure 46: Women’s Health Therapeutics Market, Market Share Analysis, (%), 2010 89

Figure 47: Women’s Health Therapeutics Market, Pfizer SWOT Analysis, 2011 91

Figure 48: Women’s Health Therapeutics Market, Eli-Lilly SWOT Analysis, 2011 92

Figure 49: Women’s Health Therapeutics Market, Merck SWOT Analysis, 2011 93

Figure 50: Women’s Health Therapeutics Market, Roche SWOT Analysis, 2011 94

Figure 51: Women’s Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2011 95

Figure 52: Women’s Health Therapeutics Market, Global, M&A Deals by Year, 2004-2011 96

Figure 53: Women’s Health Therapeutics Market, Global, M&A Deals by Type, (%), 2004-2011 97

Figure 54: Women’s Health Therapeutics Market, Global, M&A Deals by Geography, (%), 2004-2011 98

Figure 55: Women’s Health Therapeutics Market, Global, M&A Deals by Value, (%), 2004-2011 99

Figure 56: Women’s Health Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011 101

Figure 57: Women’s Health Therapeutics Market, Global, Licensing Agreements by Geography, (%), 2004-2011 102

Figure 58: Women’s Health Therapeutics Market, Global, Licensing Agreements by Value, (%), 2004-2011 103

Figure 59: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Year, 2004-2011 104

Figure 60: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Geography, (%), 2004-2011 105

Figure 61: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Value, (%), 2004-2011 106

Figure 62: GBI Research Market Forecasting Model 112

• Acute Inflammation – Pipeline Review, H1 2013
• Ovarian Disease – Pipeline Review, H1 2013
• Premenstrual Syndrome – Pipeline Review, H1 2013
• Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
• Cervical Dysplasia – Pipeline Review, H1 2013
• EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
• Female Sexual Dysfunction – Pipeline Review, H1 2013
• Menopausal Disorders – Pipeline Review, H1 2013
• Menopausal Hot Flashes – Pipeline Review, H1 2013
• Uterine Fibroids – Pipeline Review, H1 2013
• Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Dysmenorrhea – Pipeline Review, H1 2013
• Endometriosis – Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Premature Labor (Tocolysis) – Pipeline Review, H2 2012
• Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
• Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
• Premature Ovarian Failure – Pipeline Review, H2 2012
• Premenstrual Syndrome – Pipeline Review, H2 2012